Index

acamprosate, 134–135
activation likelihood estimation (ALE), 100
acute withdrawal, 85–86
addiction
behavioral definition of, 4, 12–14
behavioral progression of, 9–10
and causality, 156–157
chemical, 6–12
as chronic brain disease, 130–132
classification systems of, 6–9
clinical definition/diagnosis of, 2, 6–9
dark side of, 90–91
demography of, 5
mental disorders and, 4
phenomenology of, 4
rates of, 1, 149
stigma of, 5–6
addiction theories
allostatic, 36–38
brain disease model, 9–12
cue-elicited craving, 40
future of, 40–41
impaired response inhibition and salience attribution syndrome (iRISA), 38–40
incentive sensitization, 34–36
adolescence, 127, 149–150
Adolescent Brain Cognitive Development (ABCD) study, 32
agonists, 66
Aharonovich, E., 140
Ahmed, S. H., 12
alcohol use
action areas of, 68
and anhedonia in protracted withdrawal, 87
appetitiveness, 103
behavioral effects of, 10
brain mechanisms of, 71–73
craving studies, 98–99, 102
demographics of, 5
and dopamine, 53
electrophysiological markers, 89
and endophenotypes, 153–154
intoxication symptoms, 64–65
late positive potential (LPP), 102
pharmacological interventions, 133–135
and social class, 41
stigma of, 5
withdrawal symptoms, 83
allostatic theory, 36–38, 90–91
allosteric potentiator, 134
α power, 88–89
American Psychiatric Association (APA), 6
amotivation, 88
amphetamine use
action areas of, 66
behavioral addiction of, 9–10
amygdala volume
and alcohol use, 73
and cannabis use, 28
and the cue-elicited craving model, 40
and emotion regulation, 102
Anagnostaras, S. C., 35
anhedonia, 88
antagonists, 66
antireward system, 12
anxiety
and cannabis use, 41
and high β activity, 88–89
internet/video game addiction, 94
appetitiveness, 103–105
arterial spin labeling, 100
attention
and cognitive behavior therapy (CBT), 135
and craving, 105–106

© in this web service Cambridge University Press

www.cambridge.org
attention deficit/hyperactivity disorder (ADHD), 116–117
Babor, T. F., 5
backward masking, 106
Balleine, B. W., 137
Barrett Impulsiveness Scale, 115, 117
Bauer, L. O., 89
Begleiter, H., 69
behavior prediction, 32
behavior sensitizing experiments, 9
behavioral addiction, 12–14
behavioral drug treatment interventions, 135–137
Berridge, K. C., 35
β power and anxiety, 89–90
and craving, 101
β spectral power, 101
Bickel, W. K., 136
biochemical imaging, 27–28
biomarkers, 28
blood oxygenated level dependent (BOLD) signal, 25
Bobzean, S. A., 156
Boeijinga, P. H., 135
Boileau, L., 36
Bonson, K. R., 102
brain adolescent, 149–150
drug effects on mesocorticolimbic reward system, 11
brain disease model (addiction), 2, 9–12, 130–132
brain function during protracted withdrawal, 88
during withdrawal, 86
hijacking by drugs, 104–105
and impulsivity, 123
and intoxication, 68–73
and love, 30
measurement of, 22–24
bupropion, 134

cannabis use action areas of, 68
behavioral effects of, 10
craving, 100–101
endocannabinoid system, 53
and endophenotypes, 153
and genetics, 29
longitudinal study of, 156–157
and perceived stress, mood, 40–41
and stress, 161
treatment outcomes, 140
withdrawal symptoms, 83–84
Carroll, K. M., 134, 140
Casey, B. J., 149
Centers for Disease Control and Prevention (CDC), 43
cerebral blood flow (CBF), 86
chemical addiction, 6–12
Childress, A. R., 102–103, 104–105
Chocyk, A., 150
choline, 27
Cicero, T. J., 5
Clark, L., 121, 123
classical conditioning experiments, 9
cocaine action areas of, 68
acute withdrawal, 86
appetitiveness, 103
craving studies, 100
and dopamine, 52
during protracted withdrawal, 88
electrophysiological markers, 88–90
and the iRISA theory, 38
late positive potential (LPP), 102
pharmacological interventions, 134
treatment outcomes, 140
withdrawal symptoms, 83
cognitive behavioral models, 135–137
cognitive behavioral therapy (CBT), 136, 138, 140
cognitive impairment and addiction, 12
compulsive disorders, 12–13
Conklin, C. A., 98
contingency management, 136
Corbit, J. D., 36
Costello, M. R., 137
Index

| craving | and the allostatic theory, 38 |
| craving | and attention, 105–106 |
| craving | contextual cues, 102 |
| craving | and the cue-elicited craving model, 40 |
| craving | cue-reactivity paradigms, 99–101 |
| craving | after death, 110 |
| craving | defined and research history, 98–99 |
| craving | neurological underpinnings of, 101 |
| craving | neuromolecular mechanisms, 106–107 |
| craving | and reward system hijacking, 103–105 |
| craving | creatine, 27 |
| craving | cue-elicited craving theory, 40 |
| craving | cue-reactivity approach and craving, 99 |
| craving | and methadone, 133 |
| craving | paradigms, 99–101 |
| Dackis, C. A., 86 |
| Dagher, A., 13 |
| Daglish, M. R., 104–105 |
| Decade of the Brain, 130 |
| delay discounting, 115, 123–125, 137 |
| demographics | and drug use, 5 |
| demographics | and impulsivity, 127 |
| demographics | demography of addiction, 5 |
| depression | dendritic alterations (brain), 106–107 |
| depression | and cannabis use, 41 |
| depression | genetic risk for, 151 |
| DeWitt, S., 40 |
| diagnosis of addiction, 6–7 |
| Diagnostic and Statistical Manual of Mental Disorders (DSM), 2, 6 |
| diffusivity, 25 |
| diffusion tensor imaging (DTI), 24 |
| disulfiram, 135 |
| Domino, E. F., 69, 88 |
| dopamine | and ADHD, 116–117 |
| dopamine | in behavioral activation and effort, 56 |
| dopamine | and craving, 100 |
| dopamine | and hedonistic response, 10–11 |
| dopamine | and hormones, 156 |
| and reward learning mechanisms, 51–53 |
| and the incentive-sensitization model, 35 |
| and the iRISA theory, 38 |
| during protracted withdrawal, 87–88 |
| dopamine-depletion hypothesis, 86 |
| drug classification, 66 |
| Drug Enforcement Administration (DEA), 2 |
| drug expectations, 75 |
| drug treatment interventions | behavioral, 12, 135–137 |
| drug treatment interventions | combined approaches to, 137–139 |
| drug treatment interventions | legislation versus cost, 143–144 |
| drug treatment interventions | outcomes, 138–140 |
| drug treatment interventions | peer influence on, 142–143 |
| drug treatment interventions | pharmacological, 132–135 |
| drug treatment protocol, 131–132 |
| drugs (DEA schedule), 3 |
| Drummond, D. C., 98 |
| Ducci, F., 150, 151 |
| Dunedin Multidisciplinary Health and Development Study, 156–157 |
| Dunning, J. P., 102 |
| dysphoria, 82 |
| ecological validity (craving), 99–100 |
| ecstasy. See MDMA |
| effort–reward calculation, 56 |
| electroencephalography (EEG) and alcohol endophenotypes, 153–154 |
| endophenotype, 118, 150–155 |
| environment, 102 |
| enzyme-linked receptors, 66 |
| Ersche, K. D., 117, 118, 120, 125 |
| etiology of addiction, 6 |
| Evoy, K. E., 134 |
| excitatory post-synaptic potential, 22 |
| FBJ murine osteosarcoma viral oncogene homolog B (FosB), 106–107, 110 |
| Fehr, C., 85 |
Index

Feldstein Ewing, S. W., 136
fetal alcohol syndrome, 4
Filbey, F. M., 5, 13, 40–41, 100, 101, 103–104
final common pathway, 53–54
five-choice serial reaction time task (5CSRTT), 121, 125
food addiction, 12–13
fractional anisotropy, 25
Franken, I. H., 89, 102
Franklin, T. R., 100
functional MRI (fMRI)
and adolescence, 60
and backward masking, 105–106
and brain mechanism, 71–73
and cognitive behavioral therapy (CBT), 136
craving studies, 99, 133–134
description of, 25
and sex in addiction, 153
Gallinat, J., 13, 100
gambling addiction, 12
γ-aminobutyric acid (GABA)
and acamprosate, 134–135
and acute withdrawal symptoms, 86
and alcohol use, 68, 153
and hedonistic response, 10
gender and addiction, 5, 155–156
gen expression receptors, 66
and addiction, 5, 55–56, 150–155
and drug expectancy, 75
and impulsivity, 118
and limitations to neuroimaging, 29
ΔFosB, 106–107
George, O., 90, 100
Gerbing, D. W., 115
Giorgio, A., 1, 149
Glenn, S. W., 90
glucose metabolism, 70–71
go/no go test, 119
Gogtay, N., 1, 2, 149
Gold, M. S., 85
Goldman, D., 150, 151
Goldstein, R. Z., 38, 39, 139
Gooding, D. C., 89
Gould, K. L., 86
G protein-coupled receptor, 66
Gritz, E. R., 89
half-life (substance), 82–85
Hariri, A. R., 150, 152
Hasan, K. M., 1, 149
hedonistic set point, 35
Heinze, M., 102
Hendriks, V. M., 102
heritability, 150
Herning, R. I., 101
heroin use
electrophysiological markers, 88
hijacking the brain, 105
late positive potential (LPP), 102
withdrawal symptoms, 83
Herrmann, M. J., 102
Holden, C., 12
homeostasis, 36–38
Homer, D. W., 40
hormones and dopamine, 156
hypersensitization, 35
hypothalamic–pituitary–adrenal axis (HPA), 90
impaired response inhibition and salience attribution syndrome (iRISA), 38–40
Impulse Behavior Scale (IBS), 117
impulsivity
in adolescence, 127–128
defined, 114–116
and delaying discounting of reward, 123–125
and inhibitory control, 121
nature of, 117–120
neuropsycharmacology of, 116–117
and risky decision making, 120–121
incentive salience, 35, 47
incentive-sensitization theory, 34–36, 103–104
inhibitory control, 121, 140
inhibitory post-synaptic potential, 22
International Classification of Diseases (ICD), 2, 6
internet/video game addiction
as behavioral addiction, 14
separation anxiety, 94
interoceptive processes, 40
intoxication (drug)
action areas of, 66–68
brain mechanisms of, 68–73
defined, 64–65
modulators of, 73–75
pharmacodynamics of, 66
intraocular self-stimulation experiments, 9, 48
ion channel receptors, 66
ionic gradients, 22
Iowa gambling task (IGT), 120–121
Jarvis, M. J., 5
Jessie’s Law, 144
Johnson, T. S., 134
Kalivas, P. W., 53
Ketcherside, A., 41
Kim, J. E., 13
King, D. E., 88
Kish, S., 16
Kott, V. J., 88, 101
Kober, H., 136
Konova, A. B., 137, 139
Koob, G. F., 12, 35, 36, 37, 90–91
Kouros, A. S., 13
Kuczenski, R., 9
Kuhn, S., 13, 100
Landes, R. D., 136
late positive potential (LPP), 102
Le Moal, M., 35, 36, 37, 90–91
Lebel, C., 1, 149
Leith, N. J., 9
Lenoir, M., 12
Lewis, C. C., 136
ligands, 66
limbic cortex activation, 102
Littel, M., 89
Liu, X., 101
Loughead, J., 133
love and brain function, 30
LSD (lysergic acid diethylamide), 15, 66
magnetic resonance imaging (MRI), 12, 24–27
magnetic resonance spectroscopy (MRS),
27
magnetoencephalography (MEG), 22–23
Marijuana Problem Scale (MPS), 101
Martinotti, G., 87
masked cue task, 105–106
McDonough, B. E., 102
MDMA (3,4-
methylenedioxymethamphetamine),
15, 66
mechanisms of addiction, 9–12
memory and addiction, 56–58
mental disorders and addiction, 4
mesolimbic reward system (brain)
and behavioral addiction, 13–14
changes during addiction, 10–12
and the cue-elicited craving model, 40
as reward system, 49
metabolites (brain tissue), 27
methadone, 133
methamphetamine use, 53
monetary incentive delay task, 60
morphine, 9
motivation
and future drug use prediction, 60
and reward learning mechanisms, 47–58
motivational enhancement therapy (MET),
136
motivational interviewing (MI), 136, 138
Myrick, H., 100, 101
N-acetylaspartate (NAA), 27
Namkoong, K., 102
National Institutes of Health (NIH), 31
natural reinforcers, 12
neonatal abstinence syndrome, 4, 93
Nestler, E. J., 106
neuroimaging studies
and addiction activity, 12
and behavior prediction, 32
craving, 99–101
diffusion tensor imaging (DTI), 24
neuroimaging studies (cont.)
electroencephalography (EEG), 22–24, 69, 88–90, 101–102, 153–154
and impulsivity, 119
limitations of, 28–29
magnetic resonance imaging (MRI), 24–27
magnetic resonance spectroscopy (MRS), 27
magnetoencephalography (MEG), 22–23
of behavioral addiction, 13–14
of combined drug interventions, 137–138
positron emission tomography (PET), 12, 26–28, 52–53, 69–71, 100
single-photon emission computed tomography (SPECT), 26, 27–28
structural MRI, 24
Niaura, R. S., 98
nicotine use
action areas of, 66–68
and brain mechanism, 68–70
and craving, 100, 101–102
and the cholinergic system, 53
delay discounting, 124
demographics of, 5
pharmacological interventions, 133–134
and social class, 41
withdrawal symptoms, 83, 87
nucleus accumbens
and acute withdrawal symptoms, 86
and ADHD, 116–117
as common addiction pathway, 54
and craving, 106–107, 109
and dopamine, 49–52
Nutt, D. J., 104
O’Brien, C. P., 13
Ogawa, S., 25
opioid use
action areas of, 68
addiction from birth, 93
behavioral effects of, 10
demographics of, 5
and hedonistic response, 11
and the opioid system, 53
pharmacological interventions, 133
as public health concern, 43–45, 162
treatment cost, 143–144
opponent-process theory, 36, 90–91
Orsini, C., 82
P300, 101–102
Pagliaccio, D., 28
Papageorgiou, C. C., 89
Pavlovian conditioning, 98–99
peer recovery specialists, 142–143
pharmacodynamics, 66
pharmacological interventions, 132–135
phencyclidine (PCP), 68
phenomenology of addiction, 4
place preference, 9–10
pleasure molecule. See dopamine
Poiries, B., 69, 89, 153, 154
positron emission tomography (PET)
and brain mechanism, 69–71
craving studies, 100
dopamine studies, 27–28, 53
post-acute withdrawal syndrome, 87–88
post-traumatic stress disorder (PTSD), 15–16, 161
Potenza, M. N., 137–138
prefrontal cortex
and craving, 100, 106–107
and decision making, 120–121
and dopamine, 51–53
during withdrawal, 86
dysfunction and relapse, 85–86
and the iRISA theory, 38–39
and reinstatement, 54
pre-potent response, 115
probability discounting, 124
Probst, C. C., 12
protracted withdrawal symptoms, 87–88
psychedelic drug therapeutic benefits, 15–16
psychiatric disorders and addiction, 5
pyramidal cells, 22
radionuclotides, 27
radiotracer, 100
Index

Rangaswamy, M., 153, 154
receptors, 66
Reid, M. S., 101
reinstatement experiments
and drug relapse, 9
and final common pathway, 53–54
relapse prediction
for drug-addicted patients, 131
electrophysiological makers for, 89–90
prefrontal cortex and, 85–86
reinstatement experiments, 10
relapse prevention, 140
resting-state functional connectivity (rsFC), 71
reward deficiency syndrome, 55
reward system
and addiction, 10–12
and behavioral-drug treatment interventions, 137
and craving, 103–105
and incentive salience, 35
and motivation, 47–58
risk factors, 5, 149–150
risk decision making, 120–121
Robinson, T. E., 35, 50, 99
Roemer, R. A., 88
Salamone, J. D., 56, 57
Schacht, J. P., 28, 153, 155
Schedule I drugs, 2–3
Schneider, F., 99
school dropout rate and addiction, 4
Sell, L. A., 104
Seltenhammer, M., 109
serotonin, 68
sex addiction
appetitiveness, 103–104
as behavioral addiction, 12–13
Shaw, P., 1, 150
shopping addiction, 13
Shufman, E., 88
single-photon emission computed spectroscopy (SPECT), 27–28, 69
Sinha, R., 86
Skinner, M. D., 135
social class
and addiction, 5
and drug use, 41
Sofuoglu, M., 134, 137
Solomon, R. L., 36
stimulant use
behavioral effects of, 10
demographics of, 5
stop signal reaction time (SSRT), 119, 121, 123
stress (adolescent), 150, 161
structural MRI, 24
substance use disorder (SUD)
addiction as, 2
behavioral symptoms of, 12–13
classification systems of, 6–7
sugar addiction, 12–13
superconducting quantum interference device (SQUID), 22
Surwillo, W. W., 88
sympathomimetic action, 86
Tanabe, J., 86, 87
tanning addiction, 12, 13
Teklezi, B. G., 133
tetrahydrocannabinol (THC), 68
thalamus, 86
Tiffany, S. T., 98–99, 105
tolerance
and the allostatic theory, 36–38
brain adaptation and, 11
and substance use, 4
sugar, 12–13
tractography, 25
transduction, 66
unemployment rate and addiction, 4
Vaituzis, A. C., 1, 150
van de Laar, M. C., 102
van Eimeren, T., 12
Venables, P. H., 88
Verdejo-Garcia, A., 140
Vogeler, T., 134
Volkow, N. D., 13, 38, 39, 40, 52, 53–54, 71, 75, 85, 86, 88

wait circuit, 124
waiting, 125
Wang, G. J., 71
Warren, C. A., 102
Weeks, J. R., 9
Wexler, B. E., 136
Wierenga, L. M., 150
Winterer, G., 89
withdrawal
acute, 85–86
and the allostatic theory, 36
between systems adaptations, 90–91
brain adaptation and, 11
brain function during, 86
and dark side of addiction, 11
defined, 81–82
electrophysiological mechanisms of, 88–90
and incentive sensitization model, 35
and the iRISA theory, 39
protracted, 87–88
and substance use, 4
sugar, 12
symptoms and classification of, 82–84
Wong, D. F., 100
Worhunsky, P. D., 13
World Health Organization, 2, 6
Wrase, J., 99
Wray, J. M., 105
young adult. See adolescence
Young, K. A., 105
Zubieta, J. K., 86